Agency pledges focus on post-market safety info

Share this article:
The FDA says drug safety improvements at the agency will focus on the quality of post-market safety information received, new analytical tools and approaches for evaluating this information, and effective public communication about emerging risks—according to a speech by deputy commissioner for medical and scientific affairs Scott Gottlieb.

In what many saw as window dressing for his agency's response to the Democratic-controlled congressional oversight, Gottlieb said the new initiatives address several key areas highlighted in a recent report by the Institutes of Medicine and they should be seen as the agency making drug safety a top priority.

He said that FDA officials will seek new funding from the re-authorization of the Prescription Drug User Fee Act to gain access to more post-market database resources and other post-marketing surveillance activities.

Improving risk communication will require better tools, and more consistent approaches, Gottlieb said. “We will be developing guidance that will spell out how sponsors can rigorously evaluate their drug names, in a scientific fashion, to objectively measure whether they might present confusion.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...